# A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

> **NCT02347917** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** BBI608
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02347917
- **Lead sponsor:** Sumitomo Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-05-31
- **Final completion:** 2018-05-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347917, "A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02347917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*